Sixty-nine patients with sinonasal tumors underwent curative intent PBT including 42 patients received de novo irradiation and 27 received reirradiation. With the median follow-up for surviving patients of 26.4 months, this study reported the 3-year overall survival (OS), freedom from distant metastasis, freedom from disease progression, and freedom from locoregional recurrence for de novo irradiation were 100%, 84.0%, 77.3%, and 92.9%, and 76.2%, 47.4%, 32.1%, and 33.8%, respectively for re-RT patients. There were 11 patients with acute grade 3 toxicities.

Late toxicities occurred in 15% of patients, with no grade ≥3 toxicities. No patients developed vision loss or symptomatic brain necrosis. This study concluded that PBT may be a safe and efficacious treatment option for patients with sinonasal tumors.